Why Your CRO Should Understand Your Molecule’s Mechanism of Action
Why Your CRO Should Understand Your Molecule’s Mechanism of Action
Every therapeutic protein has a story: how it binds, where it acts, and what factors impact its function. Yet in many bioanalytical laboratories, that story never makes it past the intake. For pharmacokinetic assays designed to measure drug concentration—the focus of this discussion—that disconnect between biological understanding and technical execution creates predictable problems. Method development for large-molecule bioanalysis involves numerous technical decisions. When these decisions are made without understanding the molecule’s biology, the process becomes an inefficient trial-and-error exercise rather than hypothesis-driven optimization. Whether multiple rounds of optimization and revalidation are needed often hinges on whether the biological context informed those decisions from the outset.
The Cost of Generic Approaches
Assay format selection illustrates this disconnect. Generic method development defaults to standard approaches without considering the molecule’s biology. When your molecule’s biological complexity doesn’t fit those standard approaches, you discover this after weeks of optimization, not because the technical work was poor, but because the biological context that should have informed the initial strategy was never considered.
Generic approaches create similar problems during validation. Standard validation protocols can meet every regulatory acceptance criterion while omitting the biological conditions that will challenge the assay in actual use. Bioanalytical method validation guidance provides frameworks for validation parameters [1], but these frameworks must be applied with consideration of molecule-specific biological factors. Without the biological context, validation becomes a checklist exercise rather than a genuine stress test of assay performance under physiologically relevant conditions.
What Mechanism of Action Should Tell Us
The mechanism of action should guide the analytical strategy from the outset. The most fundamental question in assay development is whether to measure free drug, total drug, or drug-target complex, and it cannot be answered without understanding how the molecule works. Assays measuring free or partially free drug provide information on the pharmacologically active fraction, while total drug assays measure all forms, both free and fully bound to target. For molecules with high target occupancy, free-drug measurements are often more informative for PK modeling than total-drug measurements. This decision fundamentally shapes assay format, reagent selection, and data interpretation, yet it’s often made by default rather than by design when biological context is absent from intake.
Target biology should guide where optimization efforts require focused attention. Understanding the target and its biological context is fundamental to the reagent selection strategy, as emphasized in industry guidance on immunogenicity assessment [2]. Standard optimization addresses blocking conditions, incubation times, and matrix effects for every assay, but knowing your molecule’s biology reveals which parameters are likely to be problematic for your specific molecule.
- Does your target exist in multiple forms?
- Does it undergo conformational changes?
- Can it be shed or cleaved?
These biological realities determine whether distinguishing between molecular forms becomes a critical priority rather than a routine consideration. When such distinctions matter, they fundamentally shape reagent selection strategies and specificity requirements. Conversely, understanding reagent specificity when multiple molecular forms exist informs appropriate interpretation of the data. Understanding biological context prevents these limitations from being discovered further down the road.
Disease biology should reveal potential interferences before they become problems. Endogenous antibodies and matrix components are well-documented sources of interference in ligand-binding assays [3]. Autoimmune diseases are often characterized by elevated rheumatoid factor, heterophilic antibodies, or circulating immune complexes. Oncology patients may have compromised immune function, which can affect their baseline immunoglobulin levels. Inflammatory conditions alter the levels of acute-phase proteins, resulting in matrix effects. These shouldn’t be surprises that emerge during sample analysis. They should be anticipated during method development based on the patient population.
Pharmacological context completes the biological picture by informing validation requirements. If your molecule exhibits target-mediated drug disposition with a nonlinear PK profile, the validation must demonstrate reliable measurement across the full range of anticipated sample concentrations [4].
When Biology Gets Left Behind
When method development relies on generic approaches rather than biological understanding, the consequences ripple through the bioanalytical workflow. Optimization stalls without biological context to guide troubleshooting. Technical decisions default to what’s familiar or operationally convenient (commercially available reagents, standard protocols, generic optimization sequences) rather than to what’s appropriate for the specific molecule. When problems arise, troubleshooting becomes an empirical trial-and-error process rather than a hypothesis-driven investigation guided by an understanding of how the molecule interacts with its environment.
Current bioanalytical method validation guidance provides frameworks for validation parameters [1], but these must be applied with molecule-specific biological considerations. Acceptance criteria can meet regulatory guidance expectations without reflecting the molecule’s actual behavior. Dilutional linearity assessed with control samples prepared in a pooled matrix may not reflect the reality of clinical sample heterogeneity, where dilution effects may affect assay readouts differently. Validation data can be technically compliant yet fail to predict real-world assay performance.
Sample analysis reveals what method development should have addressed. Problems that would have been prevented by applying the biological context now surface during the study. The assay performs differently in actual clinical samples than it did during validation. At this point, in-study validation, additional testing during sample analysis to confirm method performance, may reveal the extent of the problem. Options are limited and costly: restrict the assay’s use, return to validation with appropriate biological considerations, or restart method development entirely. Timeline delays and additional costs are inevitable.
These aren’t random technical failures. They’re predictable outcomes when method development proceeds without the biological context necessary to make informed strategic decisions.
The Structural Challenge
In large CRO environments, specialization fragments biological understanding. Many CROs don’t have a formal intake process at all. When biological information is gathered, whether during business development or initial project discussions, the person collecting it rarely develops the method. The method development scientist has limited interaction with the validation analyst. Documentation may capture biological information, or it may only record client requests for assay type and desired sensitivity. Either way, that information doesn’t consistently inform the many technical decisions made throughout method development, validation, and sample analysis. When biological context does make it into the project file, it rarely translates into strategic thinking.
Smaller, more integrated teams have a natural advantage when the same scientists who discuss the mechanism of action during intake remain engaged through sample analysis. But size alone doesn’t solve the problem; what matters is intentional structure. Scientists collaborate from project initiation, with intake processes that prioritize biological understanding over logistics, within an organizational culture that values hypothesis-driven optimization over standardized protocols.
A Different Approach
At Immunologix Laboratories, we’ve structured our scientific operations around these principles through our Scientific Triad model. Every project is overseen by three scientists: a Principal Investigator, a Method Development Scientist, and a Translational Scientist. This core team engages with your molecule’s mechanism of action from project initiation and maintains oversight from assay optimization through to sample analysis.
This structure ensures that biological understanding informs technical decisions throughout the project lifecycle. When optimization issues arise, the biological context is immediately available to generate informed hypotheses. When sample analysis reveals unexpected results, the scientists running the assay understand the biological framework for troubleshooting. Biology doesn’t get lost between intake and execution.
If you’re evaluating CRO partners for your large molecule bioanalysis needs, we’d welcome a conversation about how understanding your molecule’s mechanism of action could improve the efficiency and quality of your bioanalytical program.
Contact us to discuss your project.
References
[1] U.S. Food and Drug Administration. M10 Bioanalytical Method Validation and Study Sample Analysis. ICH Guidance for Industry. May 2022. Available at: https://www.fda.gov/media/162903/download
[2] European Medicines Agency. Guideline on Immunogenicity Assessment of Therapeutic Proteins. EMEA/CHMP/BMWP/14327/2006 Rev 1. December 2017. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
[3] Wauthier L, Plebani M, Favresse J. Interferences in immunoassays: review and practical algorithm. Clin Chem Lab Med. 2022 Mar 18;60(6):808-820. doi: 10.1515/cclm-2021-1288. PMID: 35304841.
[4] Dua P, Hawkins E, van der Graaf PH. A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics & Systems Pharmacology. 2015;4(6):324-337. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4505827/
